Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer
By
Marie Nour Karam
Joseph Hajj
Christopher H. Crane
Paul Ramia
Fady Geara
Nadim Hamadeh
Jacob G. Scott
Stephen Grobmyer
Rachael Almond
Eileen M. O’Reilly
Carla Hajj
June 8, 2026
Clinical Scorecard: Exploring Radiogenomics and DNA Damage Response: Enhancing Biomarker-Driven Radiosensitization Strategies in Pancreatic Cancer
At a Glance
Category Detail
Condition Key Mechanisms Radiogenomics and DNA damage response (DDR) inhibitors Target Population Care Setting
Key Highlights
Radiogenomics studies genetic variation influencing radiotherapy response. Radiosensitivity index (RSI) and genomic-adjusted radiation dose (GARD) are tools for personalized radiotherapy dosing. PDAC is one of the most radioresistant malignancies. DDR inhibitors may enhance PDAC sensitivity to radiotherapy. Guideline-Based Recommendations
Diagnosis
Consider genetic profiling to assess radiosensitivity in PDAC. Management
Incorporate DDR inhibitors in treatment regimens for PDAC. Monitoring & Follow-up
Evaluate treatment response through genomic data integration. Risks
Be aware of normal tissue toxicity when administering radiotherapy. Patient & Prescribing Data
Patients diagnosed with pancreatic ductal adenocarcinoma
Clinical Best Practices
Utilize multi-omics data for predictive modeling in treatment selection. Conduct large-scale, biomarker-driven clinical trials for validation. Related Resources & Content
